Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have revolutionized cancer treatment in the recent years, affording long-term survival benefit in a broad range of cancer patients. This evidence concerns the gene CD274 and cancer.